Goldman Sachs
CABA icon

Goldman Sachs’s Cabaletta Bio CABA Stock Holding History

Goldman Sachs’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-246,500
Closed -$663K – 6593
2026
Q1 		$663K Hold
246,500
– – ﹤0.01% 5396
2025
Q4 		$540K Buy
+246,500
New +$611K ﹤0.01% 5540

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Goldman Sachs's CABA Position: Q2 2026 in Review

Goldman Sachs increased its Cabaletta Bio (CABA) stake by 182% in Q2 2026, buying an estimated $4.7M and bringing the position to 2,211,825 shares worth $6.88M. The position accounts for ﹤0.01% of the portfolio, ranked #3590.

Goldman Sachs first reported a position in CABA in Q1 2020 and has held it in 24 quarters since. The position peaked at $7.25M in Q1 2024. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Goldman Sachs held 2,211,825 shares of Cabaletta Bio worth $6.88M as of Q2 2026.
  • Goldman Sachs bought 1,428,605 Cabaletta Bio shares in Q2 2026, an estimated $4.7M.
  • Cabaletta Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3590 holding.
  • Goldman Sachs first reported a position in Cabaletta Bio in Q1 2020 and has held it in 24 quarters since.
  • Goldman Sachs's Cabaletta Bio position peaked at $7.25M in Q1 2024.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.